je.st
news
Tag: fullyear
C&C Group warns of full-year ForEx drag as four-month performance "in line" with expectations
2017-07-06 13:27:00| Daily beverage news and comment - from just-drinks.com
C&C Group has warned that a continued weakness in the value of Sterling will hit the firm's full-year performance.
Tags: with
group
line
performance
Dixons Carphone reports record full-year profits
2017-06-28 09:13:12| BBC News | Business | UK Edition
The owner of Currys and PC World said electrical sales offset a "challenging" mobile market.
Tags: reports
record
profits
dixons
Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
2017-02-02 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be Between $3.72 and $3.87, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2017 Worldwide Sales to be Between $38.6 Billion and $40.1 Billion, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Development Program U.S. Food and Drug Administration (FDA) Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score of 50 Percent or More) Without EGFR or ALK Genomic Tumor Aberrations FDA Granted Priority Review for Three Supplemental Biologics License Applications for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
financial
announces
merck
Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
2017-01-03 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 2. During the call, company executives will provide an overview of Mercks performance for the quarter and year. Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Claire Gillespie, (267) 305-0932orInvestor:Teri Loxam, (908) 740-1986Amy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Brown-Forman risks wooden full-year as barrel price drop adds to problems - Analysis
2016-09-07 14:26:00| Daily beverage news and comment - from just-drinks.com
It is only just gone Q1 for Brown-Forman but already analysts are predicting a more subdued full-year for the Jack Daniel's maker.
Tags: price
problems
analysis
drop
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »